Empagliflozin and metformin tablets
Managing type 2 diabetes effectively often requires more than just lifestyle changes—combination therapy can significantly improve blood sugar control and reduce the risk of complications. EMPATECH MET 12.5/500 is a next-generation oral antidiabetic medication that combines Empagliflozin 12.5mg and Metformin Hydrochloride (500mg) into one powerful tablet. This synergistic formula targets both insulin resistance and excess glucose reabsorption, offering comprehensive glycemic control.
Designed for adult patients with type 2 diabetes mellitus, empagliflozin and metformin tablets are a smart choice for those seeking effective, long-term blood sugar management with cardiovascular and renal protective benefits.
Key Features and Composition
Composition:
Empagliflozin 12.5mg: A sodium-glucose co-transporter-2 (SGLT2 inhibitor) that lowers blood glucose by increasing urinary glucose excretion.
Metformin Hydrochloride 500mg: A biguanide antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity.
Key Features:
Dual mechanism of action for enhanced glycemic control
Helps reduce HbA1c levels
Supports weight loss and blood pressure reduction
Offers cardiovascular and renal protection
Suitable for once or twice daily dosing
How Does It Work?
Empagliflozin and metformin tablets work through two complementary mechanisms:
Empagliflozin inhibits the SGLT2 proteins in the kidneys, reducing the reabsorption of glucose and promoting its excretion via urine. This not only lowers blood sugar levels but also contributes to weight loss and lower blood pressure.
Metformin acts primarily on the liver to decrease glucose production. It also improves insulin sensitivity in peripheral tissues and enhances glucose uptake, reducing fasting and postprandial blood sugar levels.
Together, these actions result in a significant and sustained reduction in blood glucose levels without the risk of hypoglycemia when used alone.
Usage Instructions
Dosage & Administration:
EMPATECH MET 12.5/500 should be taken orally, usually once or twice daily with meals.
Dosage should be individualized based on the patient’s current regimen, effectiveness, and tolerability.
It is important to maintain hydration, especially when taking SGLT2 inhibitors, to avoid dehydration or electrolyte imbalance.
Note: Always use under medical supervision. Regular monitoring of blood glucose, renal function, and HbA1c is essential.
Key Benefits of EMPATECH MET 12.5/500
Switching to empagliflozin and metformin tablets like EMPATECH MET 12.5/500 offers a wide range of benefits:
✅ Effective blood sugar control through dual action
✅ Helps reduce body weight and waist circumference
✅ Improves insulin sensitivity and glucose metabolism
✅ Reduces risk of cardiovascular events in patients with diabetes
✅ Provides renal protection by lowering albuminuria and preserving kidney function
✅ Lower risk of hypoglycemia compared to sulfonylureas or insulin
✅ Convenient fixed-dose combination minimizes pill burden
Who Should Use It?
EMPATECH MET 12.5/500 is indicated for:
Adults with type 2 diabetes mellitus not adequately controlled by metformin alone
Patients with established cardiovascular disease or high cardiovascular risk
Individuals aiming for weight reduction as part of diabetes therapy
Patients seeking a modern, evidence-based diabetes management plan
Potential Side Effects
While generally well-tolerated, empagliflozin and metformin tablets may have some side effects:
Common side effects:
Urinary tract infections (due to increased glucose in urine)
Genital fungal infections
Nausea or stomach upset
Diarrhea or flatulence (mostly from metformin)
Dehydration or increased urination
Rare but serious:
Lactic acidosis (associated with metformin in patients with poor kidney function)
Ketoacidosis (rare but possible with SGLT2 inhibitors)
Precautions:
Not recommended in type 1 diabetes or for diabetic ketoacidosis
Use with caution in renal impairment
Avoid in cases of severe dehydration
Conclusion
For people living with type 2 diabetes, EMPATECH MET 12.5/500 offers a smart, modern approach to managing blood sugar levels. By combining empagliflozin and metformin tablets, it delivers powerful glycemic control, helps manage weight and blood pressure, and protects heart and kidney health. Its once- or twice-daily dosing makes it a convenient and effective choice for long-term diabetes care.
About The Company
Steris Healthcare Pvt Ltd, widely recognized as Sterispharma, was established in February 2018 by a team of seasoned experts from the pharmaceutical sector. Based in Navi Mumbai, the company is proudly certified by WHO, GMP, and ISO, underscoring its unwavering commitment to quality and patient safety. Sterispharma is driven by a mission to make affordable, premium-quality medicines accessible throughout India, adhering strictly to WHO-recommended standards. Through its user-friendly online pharmacy platforms, customers can effortlessly order medications with home delivery services.
Sterispharma boasts an extensive portfolio of healthcare solutions, ranging from treatments for rare diseases to essential everyday healthcare needs. Their comprehensive product lineup addresses multiple therapeutic areas including Cardiology, Asthma, Respiratory Disorders, Nasal Care, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infective/Antibiotic Therapy, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medications are easily available for online purchase through their official websites — Sterisonline, Sterisindia, and Sterispharma — offering a seamless and reliable healthcare experience.
For further information
Email: info@sterispharma.com / contact@sterispharma.com
Call/WhatsApp: 8209542042 , 8824175417
